BIOMEDICAL RESEARCH FOUNDATION, ACADEMY...
Desconocido
Mostrando
1
al
20
de
110
resultados
PICKED: PersonalIzed medicine in Chronic KidnEy Disease
IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
participó en un
HORIZON EUROPE:
HORIZON-MSCA-2023-DN-01
In 2017, on a world scale the total number of individuals with chronic kidney disease, acute kidney injury, and those on renal replacement t...
2024-06-26 - 2028-09-30 | Financiado
2024-06-26 - 2028-09-30 | Financiado
PROMOTE: PRostate cancer OMics Oriented inTErvention
PROMOTE focuses on multidisciplinary education of doctoral candidates (DCs) in -omics and artificial intelligence (AI) mediated intervention...
2024-06-24 - 2028-08-31 | Financiado
2024-06-24 - 2028-08-31 | Financiado
STEPUPIORS: TWINNING FOR A EUROPEAN CONSORTIUM OF RECTAL CANCER RESEARCH INSTITUTIONS THROUGH STEPPING UP SCIENT...
IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
participó en un
HORIZON EUROPE:
HORIZON-WIDERA-2021-ACCESS-03
"Neoadjuvant chemoradiotherapy (CRT) is the gold standard in locally advanced rectal cancer (LARC), but the response is not uniform among pa...
2022-07-14 - 2025-09-30 | Financiado
2022-07-14 - 2025-09-30 | Financiado
LiverTarget: Next generation advanced RNA inhibition therapy to treat cardiometabolic disease
IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
participó en un
HORIZON EUROPE:
HORIZON-HLTH-2021-TOOL-06
RNA Therapeutics comprise a new rapidly expanding category of drugs including small interfering RNAs (siRNA) and messenger RNAs (mRNA) that...
2022-05-24 - 2027-04-30 | Financiado
2022-05-24 - 2027-04-30 | Financiado
UNDINE: The human genetic and immunological determinants of the clinical manifestations of SARS-CoV-2 infect...
IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
participó en un
HORIZON EUROPE:
HORIZON-HLTH-2021-DISEASE-04
"The consequences of SARS-CoV-2 exposure range from a lack of infection to lethal COVID-19. This immense inter-individual clinical variabili...
2022-05-20 - 2026-05-31 | Financiado
2022-05-20 - 2026-05-31 | Financiado
ISIDORe: Integrated Services for Infectious Disease Outbreak Research
IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
participó en un
HORIZON EUROPE:
HORIZON-INFRA-2021-EMERGENCY-02
The ISIDORe consortium, made of the capacities of European ESFRI infrastructures and coordinated networks, proposes to assemble the largest...
2022-02-09 - 2025-07-31 | Financiado
2022-02-09 - 2025-07-31 | Financiado
ALLODD: Allostery in Drug Discovery
IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
tramitó un
H2020:
H2020-MSCA-ITN-2020
Most current drugs are designed to bind directly to the primary active sites (also known as orthosteric sites) of their biological targets....
2021-05-28 - 2025-08-31 | Financiado
2021-05-28 - 2025-08-31 | Financiado
UroPrint: Urinary bladder bioprinting for fully autologous transplantation
IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
tramitó un
H2020:
H2020-FETOPEN-2018-2020
A number of conditions, including trauma, inflammation, incontinence, overactive bladder, renal impairments, neurological disorders (like sp...
2021-03-12 - 2025-08-31 | Financiado
2021-03-12 - 2025-08-31 | Financiado
InRegen: Fine tuning the inflammatory response following cardiac injury to promote cardiac regeneration
IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
tramitó un
H2020:
H2020-MSCA-IF-2020
The pronounced inability of adult human/mammalian heart to regenerate causes millions of deaths following cardiac insult, particularly in th...
2021-02-25 - 2023-03-14 | Financiado
2021-02-25 - 2023-03-14 | Financiado
Tumor-LN-oC: Tumor and Lymph Node on Chip for cancer studies
IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
participó en un
H2020:
H2020-NMBP-TR-IND-2018-2020
The lymphatic system and lymph nodes (LNs) are an integral part of our adaptive immune system and many tumors exploit lymphatic vessels to s...
2020-11-06 - 2025-10-31 | Financiado
2020-11-06 - 2025-10-31 | Financiado
RegSign: A multi parametric Regulatory T cell Atlas in cancer to predict immunotherapy response adverse auto...
IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
tramitó un
H2020:
ERC-2020-STG
The advent of immune checkpoint inhibitors (ICI), that target regulatory pathways in T cells to unleash antitumor immune responses, has revo...
2020-10-27 - 2025-12-31 | Financiado
2020-10-27 - 2025-12-31 | Financiado
SAFEMILK: Innovative technology for milk safety
IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
participó en un
H2020:
H2020-MSCA-RISE-2020
The proposal is focused on the development of novel complex assay for evaluation of milk safety, which is important for dairy industry to as...
2020-10-22 - 2025-04-30 | Financiado
2020-10-22 - 2025-04-30 | Financiado
B1MG: Beyond 1M Genomes
IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
participó en un
H2020:
H2020-SC1-DTH-2018-2020
The Beyond 1 Million Genomes (B1MG) consortium will establish the support and coordination structure for the European 1+ Million Genomes ini...
2020-06-04 - 2023-10-31 | Financiado
2020-06-04 - 2023-10-31 | Financiado
HBP SGA3: Human Brain Project Specific Grant Agreement 3
IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
participó en un
H2020:
The last of four multi-year work plans will take the HBP to the end of its original incarnation as an EU Future and Emerging Technology Flag...
2020-06-03 - 2023-09-30 | Financiado
2020-06-03 - 2023-09-30 | Financiado
EXAUTOIMMUNE: Extracellular vesicles transcriptomics unravelling the role of short non coding RNAs in autoimmuni...
IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
tramitó un
H2020:
H2020-MSCA-IF-2019
It is estimated that over 36 million Europeans suffer from an autoimmune disease (AID) and according to the European
League against Rheumati...
2020-04-10 - 2022-09-30 | Financiado
2020-04-10 - 2022-09-30 | Financiado
* No se disponen de datos de la empresa actual.